The challenge of polypharmacy in cardiovascular medicine

Fundamental and Clinical Pharmacology

Volumn 24, Issue 1, 2010, Pages 9-17

  Volpe, Massimo ^a,b   Chin, Diana ^a   Paneni, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular disease; Challenge; Polypharmacy; Preventive polypill

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; COUMARIN DERIVATIVE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYCAP; SPIRONOLACTONE; UNCLASSIFIED DRUG;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; GASTROINTESTINAL TOXICITY; GOUT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; PATIENT COMPLIANCE; PILL; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; THROMBOEMBOLISM;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MIDDLE AGED; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK FACTORS;

EID: 74049100437     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00757.x     Document Type: Review

References (83)

1. Abegunde D.O., Mathers C.D., Adam T., Ortegon M., Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet (2007) 370 1929 1938.
2. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS. Med. (2006) 3 2011 2030.
3. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the USA, 1999-2004. JAMA (2006) 295 1549 1555.
4. Ghandehari H., Le V., Kamal-Bahl S., Bassin S.L., Wong N.D. Abdominal obesity and the spectrum of global cardiometabolic risks in USA adults. Int. J. Obes. (Lond). (2009) 33 239 248.
5. Haslam D.W., James W.P. Obesity. Lancet (2005) 366 1197 1209.
6. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27 1047 1053.
7. Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N. Engl. J. Med. (2007) 356 213 215.
8. Alexander C.M. The coming of age of the metabolic syndrome. Diabetes Care (2003) 26 3180 3181.
9. Grundy S.M. Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. (2008) 28 629 636.
10. Vaccaro O., Stamler J., Neaton J.D. Sixteen-year coronary mortality in black and white men with diabetes screened for the multiple risk factor intervention trial (MRFIT). Int. J. Epidemiol. (1998) 27 636 641.
11. Howard B.V., Best L.G., Galloway J.M. et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 29 391 397.
12. Wang C., Hou X., Bao Y. et al. The metabolic syndrome increased risk of cardiovascular events in Chinese - a community based study. Int. J. Cardiol. (2008) in press.
13. http://www.un.org/esa/population/unpop.htm
14. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (2003) 326 1423 1427.
15. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) 326 1427 1431.
16. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 335 827 838.
17. Antithrombatic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324 71 86.
18. Gurwitz J.H. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch. Intern. Med. (2004) 164 1957 1959.
19. Tocci G., Sciarretta S., Volpe M. Development of heart failure in recent hypertension trials. J. Hypertens. (2008) 26 1477 1486.
20. Aronow W.S. Management of the older person with atrial fibrillation. J. Am. Geriatr. Soc. (1999) 47 740 748.
21. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation (2007) 26 3213 3223.
22. Benjamin E.J., Levy D., Vaziri S M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271 840 844.
23. Boyd C.M., Darer J., Boult C., Fried L.P., Boult L., Wu A.W. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA (2005) 294 716 724.
24. Grundy S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. (2006) 5 295 309.
25. Hanlon J.T., Schmader K.E., Ruby C.M., Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J. Am. Geriatr. Soc. (2001) 49 200 209.
26. Hajjar E.R., Cafiero A.C., Hanlon J.T. Polypharmacy in elderly patients. Am. J. Geriatr. Pharmacother. (2007) 5 345 351.
27. Jörgensen T., Johansson S., Kennerfalk A., Wallander M.A., Svärdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann. Pharmacother. (2001) 35 1004 1009.
28. Veehof L., Stewart R., Haaijer-Ruskamp F., Jong B.M. The development of polypharmacy. A longitudinal study. Fam. Pract. (2000) 17 261 267.
29. Junius-Walker U., Theile G., Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam. Pract. (2007) 24 14 19.
30. Haider S.I., Johnell K., Thorslund M., Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992-2002. Int. J. Clin. Pharmacol. Ther. (2007) 45 643 653.
31. Nobili A., Tettamanti M., Frattura L. et al. Drug use by the elderly in Italy. Ann. Pharmacother. (1997) 31 416 422.
32. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the USA: the Slone survey. JAMA (2002) 287 337 344.
33. Qato D.M., Alexander G.C., Conti R.M., Johnson M., Schumm P., Lindau S.T. Use of prescription and over-the-counter medications and dietary supplements among older adults in the USA. JAMA (2008) 300 2867 2878.
34. Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N. Engl. J. Med. (2008) 358 1547 1559.
35. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 363 2022 2031.
36. Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Gissi-HF Investigators. Lancet (2008) 372 1223 1230.
37. Fox KM; European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362 782 788.
38. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Beautiful investigators.ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 372 807 816.
39. Mancia G., De Backer G., Dominiczak A. et al. ESH-ESC task force on the management of arterial hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J. Hypertens. (2007) 25 1751 1762.
40. Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Task force for diagnosis and treatment of acute and chronic heart failure 2008 of European society of cardiology. Eur. Heart J. (2008) 29 2388 2442.
41. Van de Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology. Eur. Heart J. (2008) 29 2909 2945.
42. Steinman M.A., Landefeld C.S., Rosenthal G.E., Berthenthal D., Sen S., Kaboli P.J. Polypharmacy and prescribing quality in older people. J. Am. Geriatr. Soc. (2006) 54 1516 1523.
43. Kuijpers M.A., van Marum R.J., Egberts A.C., Jansen P.A. Relationship between polypharmacy and underprescribing.; OLDY (OLd people Drugs & dYsregulations) study group. Br. J. Clin. Pharmacol. (2008) 65 130 133.
44. Lee D.S., Tu J.V., Juurlink D.N. et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA (2005) 294 1240 1247.
45. Choudhry N.K., Anderson G.M., Laupacis A., Ross-Degnan D., Normand S.L., Soumerai S.B. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ (2006) 332 141 145.
46. Ko D.T., Mamdani M., Alter D.A. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA (2004) 291 1864 1870.
47. Soumerai S.B., McLaughlin T.J., Spiegelman D., Hertzmark E., Thibault G., Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA (1997) 277 115 121.
48. Aronson J.K. A prescription for better prescribing. Br. J. Clin. Pharmacol. (2006) 61 487 491.
49. Hajjar E.R., Hanlon J.T., Sloane R.J. et al. Unnecessary drug use in frail older people at hospital discharge. J. Am. Geriatr. Soc. (2005) 53 1518 1523.
50. Schmader K., Hanlon J.T., Weinberger M. et al. Appropriateness of medication prescribing in ambulatory elderly patients. J. Am. Geriatr. Soc. (1994) 42 1241 1247.
51. Johnson J.A., Bootman J.L. Drug-related morbidity and mortality. A cost-of-illness model. Arch. Intern. Med. (1995) 155 1949 1956.
52. Ernst F.R., Grizzle A.J. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am. Pharm. Assoc. (Wash.) (2001) 41 192 199.
53. White T.J., Arakelian A., Rho J.P. Counting the costs of drug-related adverse events. Pharmacoeconomics (1999) 15 445 458.
54. The Rales Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure [the randomized aldactone evaluation study (RALES). Am. J. Cardiol. (1996) 78 902 907.
55. Juurlink D.N., Mamdani M.M., Lee D.S. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N. Engl. J. Med. (2004) 351 543 551.
56. Rapezzi C., Biagini E., Bellis P. et al. EASY investigators exploring the gap between national cholesterol education program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. J. Cardiovasc. Med. (Hagerstown) (2008) 9 878 887.
57. Staessen J.A., Gasowski J., Wang J.G. et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet (2000) 11 865 872.
58. Monane M., Bohn R.L., Gurwitz J.H., Glynn R.J., Levin R., Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am. J. Hypertens. (1997) 10 697 670.
59. Fletcher A.E. Adverse treatment effects in the trial of the European working party on high blood pressure in the elderly. Am. J. Med. (1991) 90 42S 44S.
60. Gurwitz J.H., Avorn J., Bohn R.L., Glynn R.J., Monane M., Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA (1994) 272 781 786.
61. Chapman R.H., Benner J.S., Petrilla A.A. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. (2005) 165 1147 1152.
62. Chapman R.H., Petrilla A.A., Benner J.S., Schwartz J.S., Tang S.S. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging (2008) 25 885 892.
63. Avorn J., Monette J., Lacour A. et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA (1998) 279 1458 1462.
64. Yang C.C., Jick S.S., Testa M.A. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br. J. Clin. Pharmacol. (2003) 56 84 91.
65. Sasich L.D., Wolfe S.M., Pearson C., Swankin D.A., Levin A.A., Beard J. The national council on patient information and education. JAMA (1997) 278 1491 1492.
66. Agarwal S., Tang S.S., Rosenberg N. et al. Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy? Am. J. Ther. (2009) 16 119 126.
67. Wald N.J., Law M.R. A strategy to reduce CV disease by more than 80%. BMJ (2003) 326 1419 1423.
68. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study; INTERHEART study investigators. Lancet (2004) 364 937 952. (Pubitemid 39208455)
69. Mahmud A., Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents - a preliminary report. Hypertension (2007) 49 272 275.
70. Hippisley-Cox J., Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ (2005) 330 1059 1063.
71. Yusuf S., Pais P., Afzal R. et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Indian polycap study (TIPS). Lancet (2009) 373 1341 1351.
72. Eidelman R.S., Hebert P.R., Weisman S.M., Hennekens C.H. An update on aspirin in the primary prevention of CV disease. Arch. Intern. Med. (2003) 163 2006 2010.
73. Ridker P.M., Cook N.R., Lee I.M. et al. A randomized trial of low-dose aspirin in the primary prevention of CV disease in women. N. Engl. J. Med. (2005) 352 1293 1304.
74. Wald N.J., Watt H.C., Law M.R., Weir D.G., McPartlin J., Scott J.M. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch. Intern. Med. (1998) 158 862 867.
75. Gaziano T.A., Opie L.H., Weinstein M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 368 679 686.
76. Sleight P., Pouleur H., Zannad F. Benefits, challenges, and registerability of the polypill. Eur. Heart J. (2006) 27 1651 1656.
77. Rochon P.A., Gurwitz J.H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ (1997) 315 1096 1099.
78. Col N., Fanale J.E., Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch. Intern. Med. (1990) 150 841 845.
79. Grymonpre R.E., Mitenko P.A., Sitar D.S., Aoki F.Y., Montgomery P.R. Drug-associated hospital admissions in older medical patients. J. Am. Geriatr. Soc. (1988) 36 1092 1098.
80. Schmader K.E., Hanlon J.T., Pieper C.F. et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am. J. Med. (2004) 116 394 401.
81. Zarowitz B.J., Stebelsky L.A., Muma B.K., Romain T.M., Peterson E.L. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy (2005) 25 1636 1645.
82. Fillit H.M., Futterman R., Orland B.I. et al. Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. Am. J. Manag. Care. (1999) 5 587 594.
83. Muir A.J., Sanders L.L., Wilkinson W.E., Schmader K. Reducing medication regimen complexity: a controlled trial. J. Gen. Intern. Med. (2001) 16 77 82.